🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 41 of 857 · Phase 3 first, then by program name

  1. Capecitabine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  2. Capecitabine Accord 150 mg film-coated tablets, Fluorouracil 25 mg/ml Solution for Injection or Infusion, Irinotecan Accord 20 mg/ml Solution à diluer pour perfusion, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion

    Ningbo Cancer Hospital

    Stage III colorectal cancer

    phase 3 small molecule active

    1 trial

  3. Capecitabine monotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  4. Capecitabine plus temozolamide

    Hospital Authority, Hong Kong

    Neuroendocrine Neoplasia's (NENs)

    phase 3 small molecule active

    1 trial

  5. Capecitabine(Aibin)

    The First People's Hospital of Lianyungang

    Stage III Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  6. Capivasertib

    AstraZeneca

    Triple Negative Breast Neoplasms

    phase 3 small molecule active

    1 trial

  7. Capivasertib, Faslodex 250 mg solution for injection., Placebo to Capivasertib, Capivasertib

    AstraZeneca AB

    Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer

    phase 3 small molecule active

    1 trial

  8. Capivasertib, Placebo for capivasertib film-coated tablet for oral use, ABIRATERONE ACETATE, Capivasertib

    AstraZeneca AB

    Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency

    phase 3 small molecule active

    1 trial

  9. Capmatinib

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule terminated

    1 trial

  10. Capox chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  11. Capsaicin

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetic Polyneuropathy

    phase 3 small molecule completed

    1 trial

  12. Capsule to match PF-06651600 (Ritlecitinib) 50 mg, Ritlecitinib tosilate, DEXAMETHASONE, Capsule to match pf-06651600 (ritlecitinib) 100 mg, Ritlecitinib Tosilate

    Pfizer Australia Pty Ltd

    NON SEGMENTAL VITILIGO

    phase 3 small molecule active

    1 trial

  13. Carbetocin

    United Therapeutics Europe Ltd

    Post Partum Haemorrhage

    phase 3 small molecule completed

    1 trial

  14. Carbetocin

    Acadia Pharmaceuticals B.V.

    Hyperphagia in Prader-Willi Syndrome

    phase 3 small molecule active

    2 trials

  15. Carbetocin Nasal Spray

    Lacuna Pharma Pty Ltd

    Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS)

    phase 3 small molecule active

    1 trial

  16. Carbetocin Nasal Spray, Placebo to match carbetocin 11.4 mg/ml (2ml /vial)

    Lacuna Pharma Pty Ltd

    Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS)

    phase 3 small molecule active

    1 trial

  17. Carboplatin

    Teva Pharma GmbH

    Tubular Breast Cancer Stage II

    phase 3 small molecule completed

    1 trial

  18. Carboplatin

    Hoffmann-La Roche

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  19. Carboplatin

    Alaunos Therapeutics

    Extensive-Stage Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  20. Carboplatin

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule active

    1 trial

  21. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DS-8201a

    Daiichi Sankyo

    HER2-expressing endometrial cancer (IHC 3+/2+)

    phase 3 small molecule active

    1 trial

  22. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ribozar 1 g Pulver zur Herstellung einer Infusionslösung, Datopotamab deruxtecan, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Daiichi Sankyo

    Locally Advanced or Metastatic Urothelial Carcinoma

    phase 3 small molecule active

    1 trial

  23. Cardioblate® Surgical Ablation System

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rheumatic Valve Disease

    phase 3 other active

    1 trial

  24. CardiolRx

    Cardiol Therapeutics

    Recurrent Pericarditis

    phase 3 small molecule active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources